News

TeraWulf (NASDAQ: WULF) announced a 20‑year lease with AI model maker Anthropic for its Hawesville, Kentucky data center. The contract, worth $19 billion, will bring 401 MW of computing power online by mid‑2027 and generate $19 billion in contracted revenue by early 2028. The lease also includes two five‑year renewal options, potentially extending...

Full article

Over the past year, EyePoint’s share price has outperformed the market by nearly 25%, delivering returns twice that of broader indices. All twelve analysts covering EYPT continue to recommend a Buy, reflecting confidence in the company’s prospects. The pipeline is built on proprietary bio‑erodible Durasert E technology, aimed at treating serious re...

Full article

EyePoint, Inc. (NASDAQ:EYPT) received a new price target of $65 from analyst Andreas Argyrides, up from $29, while maintaining a Buy rating. The update highlights a “de‑risked, single‑asset, catalyst‑rich story,” with key Phase 3 readouts for DURAVYU in wet age‑related macular degeneration (AMD) expected in August 2026 and October 2026. The two lar...

Full article

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The company has out‑licensed the rights to AGAMREE in several territories, including North America, China, Japan, South Korea, Australia, and New ...

Full article

AGAMREE’s efficacy and safety profile have been demonstrated in several studies, including the pivotal Phase 2b VISION‑DMD study, where it met its primary endpoint by showing a statistically significant improvement in Time to Stand velocity compared to placebo. Long‑term data from up to eight years of AGAMREE treatment also showed durable efficacy...

Full article

The study’s findings support the dissociative corticosteroid profile of AGAMREE, which selectively binds to the glucocorticoid receptor and triggers anti‑inflammatory activity while reducing systemic effects associated with long‑term conventional corticosteroid therapy. The company has an exclusive license agreement with Catalyst for commercializat...

Full article

Santhera Pharmaceuticals Holding AG has announced top-line results from a two-part Phase 1 clinical study of AGAMREE, conducted by its North American licensing partner, Catalyst Pharmaceuticals. The study evaluated the glucocorticoid and anti-inflammatory activity of AGAMREE while assessing immunosuppressive effects. Results showed that AGAMREE dem...

Full article

The increased stake by a major institutional investor like BlackRock could potentially impact the company's governance structure, strategic direction, or even mergers and acquisitions. Investors are advised to stay informed about Caledonia Mining Corporation's developments and monitor any potential changes in its shareholder composition.

Full article

It is essential for investors to monitor this development as it may have implications for Caledonia's future operations and financial performance. The company's management team will need to consider the interests of its significant shareholders when making key decisions.

Full article

Notably, BlackRock's indirect holdings are minimal at 3.410%, indicating that the majority of its stake in Caledonia Mining Corporation is through direct shareholding. As a major shareholder, BlackRock's influence on the company's decisions and strategies may be substantial.

Full article